Physician profile
Danuta Kurstein
NPI 1326083593
$6,416.94
in general payments reported to CMS, 2019-2025
26 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $1,057 · 2021: $1,273 · 2022: $846 · 2023: $698 · 2024: $323 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,297.33 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,006.89 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $652.12 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $614.16 | 2021-2023 | Uzedy |
| Lilly USA, LLC | $608.47 | 2019-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $443.46 | 2020-2023 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $337.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $173.66 | 2019-2020 | |
| Pfizer INC. | $166.94 | 2019-2023 | |
| Astellas Pharma US INC | $146.78 | 2019-2023 | Veozah |
| Abbvie INC. | $146.50 | 2021-2022 | |
| Exact Sciences Corporation | $136.64 | 2023-2024 | Cologuard Collection Kit |
| Biogen, INC. | $100.00 | 2021 | |
| Sumitomo Pharma America, INC. | $94.65 | 2024-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $94.38 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.19 | 2019-2022 | |
| Allergan, INC. | $60.40 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.37 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.76 | 2019-2020 | |
| Linus Health, INC. | $26.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.80 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $24.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.68 | 2023 | Quviviq |
| Amgen INC. | $20.82 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $19.48 | 2019 | |
| Dexcom, INC. | $16.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danuta Kurstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.